Pfizer strikes deal with China's 3SBio to license cancer drug 辉瑞获得除中国市场外的独家授权。签署合同后立即支付12.5亿美元，然后根据协议最多付48亿美元，并支付2位数的百分比销售提成 三生制药的抗癌成果对肺癌，直肠癌和妇科肿瘤有非常好的效果
Licensing agreements for Chinese drug candidates have surged, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies in 2024. The total deal value of innovator drug licensing agreements involving Chinese biopharma licensors has surged 66%, from $16.6 billion in 2023 to $41.5 billion in 2024, reaching a five-year high, according to GlobalData’s Pharma Intelligence Center Deals Database. Increased Chinese government investments in biopharma innovation, faster and more affordable clinical trials and improved drug quality all make licensing from China more efficient and cost-effective. Biopharma companies globally have turned to licensing agreements as a strategy to access innovative drugs and strengthen pipelines as merger and acquisition investment declined in 2024. However, the proposed US BIOSECURE Act (potentially to be enacted in 2025) would prohibit federal funding for US biotech using Chinese biotech services. Additionally, the America First Investment Policy (announced on 21 February 2025) aims to restrict Chinese investments in the US biotech sector and proposes tariffs on China that could further strain supply chains and increase costs. These measures could increase geopolitical tensions, limiting Chinese biopharma’s access to US funding, partnerships and market opportunities. In December 2024, Merck expanded its oncology pipeline, licensing LM-299, a Phase II PD-1/VEGF bispecific antibody, from LaNova Medicines in a deal worth up to $3.28 billion. Biopharmaceutical companies increasingly focus on licensing monoclonal antibodies and antibody-drug conjugates (ADCs), expanding their portfolios with advanced targeted therapies. Monoclonal antibody licensing from China rose 43% to $11.3 billion, while ADC licensing grew 10% to $10 billion in 2024. In January 2024, Novartis signed a $4.35 billion deal with Shanghai Argo Biopharmaceutical, securing an exclusive licence outside Greater China for a Phase I/IIa cardiovascular asset and a global licence for another Phase I asset, with options for two more.
辉瑞获得除中国市场外的独家授权。签署合同后立即支付12.5亿美元，然后根据协议最多付48亿美元，并支付2位数的百分比销售提成
三生制药的抗癌成果对肺癌，直肠癌和妇科肿瘤有非常好的效果
系统提示：若遇到视频无法播放请点击下方链接
https://www.youtube.com/embed/EapmuhROMGs
三生制药董事长和总裁是58岁的娄丹少将，为以前沈后军事医学研究所微生物免疫研究室主任。
中企在药物开发上厉害，搞得辉瑞居然和中国军方高官合作，简直反了
根据协议，三生制药将获得12.5亿美元不可退还且不可抵扣的首付款，以及最高可达48亿美元的开发、监管批准和销售里程碑付款。公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。此外，辉瑞将于协议生效日认购三生制药价值1亿美元的普通股股份。
SSGJ-707是三生制药基于CLF2专利平台开发的靶向PD-1/VEGF双特异性抗体，可同时抑制PD-1和VEGF双靶点。II期临床阶段性分析数据显示，SSGJ-707在非小细胞肺癌（NSCLC）患者的治疗上获得了优异的客观缓解率（ORR）和疾病控制率（DCR），无论单药还是与化疗联用，均展示出显著的抗肿瘤活性和良好的安全性，具有best-in-class（同类最优）的潜力。4月17日，SSGJ-707获国家药监局突破性治疗药物认定，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌（NSCLC）。此前，SSGJ-707已获得FDA的IND批准。而除非小细胞肺癌外，SSGJ-707用于治疗结直肠癌、妇科肿瘤等领域的临床研究也在推进中。
此次合作是三生制药国际化征程上一个重要里程碑。其不仅证明SSGJ-707优异的临床效果已获得国际顶尖认可，也验证了公司自主创新研发体系的国际竞争力，显著提升了公司在肿瘤治疗领域的全球话语权，有力地推进了公司的国际化步伐。同时，此次合作也将为三生制药带来强劲的财务回报，助力公司研发体系升级，推动三生制药更好地融入全球生物医药产业价值链。
三生制药董事长兼首席执行官娄竞博士表示：“我们非常高兴能与辉瑞这样的全球顶尖药企达成合作。辉瑞丰富的开发经验及国际化视野将大幅加快SSGJ-707的全球研发及商业化进展，也将有助于三生制药的全球化战略进一步提速。既往临床数据表明，SSGJ-707具有为患者带来显著临床获益的巨大潜力。我们相信，双方的携手将有助于最大程度挖掘SSGJ-707的临床价值，未来SSGJ-707有望以最快的速度在全球范围进行开发和商业化，为全球患者带去突破性的治疗方案。”
关于三生制药
三生制药是一家集研发、生产和销售为一体的生物制药领军企业，致力于以高品质的药品提高患者生存质量，为人类健康造福。目前，公司拥有100余项国家发明专利授权，40余种上市产品，覆盖肾科、肿瘤科、自身免疫性疾病、眼科及皮肤科等多种治疗领域。公司拥有抗体药物国家工程研究中心以及生物药和化药双平台的4大研发中心，共有30种在研产品，4大生产基地及4大CDMO基地。未来，三生制药将继续秉持“珍爱生命、关注生存、创造生活”的理念，全力打造全球领先的中国生物制药企业。请访问www.3sbio.com获取更多信息。
关于辉瑞：为患者带来改变其生活的突破创新
在辉瑞，我们致力于运用科学以及我们的全球资源来提供能延长并明显改善人类寿命的治疗。在医疗卫生产品（包括创新药和疫苗）的探索、研发和生产过程中，我们均建立了质量、安全和价值标准。每天，发达和新兴市场的辉瑞员工都致力于推进健康，以及能够应对我们这个时代最为棘手的疾病的预防和治疗方案。辉瑞还与世界各地的医疗卫生专业人士、政府和社区合作，支持世界各地的人们能够获得更为可靠和可承付的医疗卫生服务。这与辉瑞作为一家卓越的创新生物制药公司的责任是一致的。175多年来，辉瑞一直努力为人们提供更好、更优质的服务。如需了解更多信息，请登录 www.pfizer.com。
低调！别影响了高等华人们的优越感。
你看你楼下6楼就是，影响人家优越感了。
美国禁华为不就是说华为的任正非当过兵，然后华为就是军方有关系的公司？任正非的官比三生的老板小太多了。
要有点幽默感好吗？
从另外一个方面可以看出，中国在落后的医疗开发上开始奋起直追了，这么一笔大生意确实很牛，辉瑞会带动更多的西方公司来华寻找类似的医疗创新企业合作，又会推动中国的发展。
剩下的皇冠上明珠不多了吧？芯片是唯一最后的难关？不过中国的芯片目前已经超过珠峰的半山腰了，而且在加速追赶。
至于AI 已经齐头并进了，2年内有希望领先。
不是辉瑞带动更多西方公司来华寻找创新药，是辉瑞再不买就落后了，在PD(L)-1/VEGF 双抗这个靶点里，已经有三家中国公司被买了： 康方把这个靶点的药卖给了Summit 普米斯卖给了德国的BioNtech 礼新医药把这个靶点的药卖给了Merck
为啥生物医药独霸世界的美国大医药研发公司,在这个双抗方面，落后于中国的小公司？
没有啊，从十几年前开始大制药公司就要靠收购小公司来丰富自己的管线，从头到尾由大药厂做出来的药占比越来越少。
研发新药要靠大量的生物化学劳动力，国内占优势。以后这种合作收购案例会越来越多。
天天在这里坐井观天，这是几年前的新闻，大部分人都知道的事了
https://www.wsj.com/health/pharma/the-drug-industry-is-having-its-own-deepseek-moment-68589d70 现在全世界几乎1/3的制药licensing deal都是中国的 中国制药界可以彻底毁掉美国和欧洲的的制药行业，根本竞争不过中国，美国生化股票最近几年都惨得很
Licensing agreements for Chinese drug candidates have surged, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies in 2024. The total deal value of innovator drug licensing agreements involving Chinese biopharma licensors has surged 66%, from $16.6 billion in 2023 to $41.5 billion in 2024, reaching a five-year high, according to GlobalData’s Pharma Intelligence Center Deals Database. Increased Chinese government investments in biopharma innovation, faster and more affordable clinical trials and improved drug quality all make licensing from China more efficient and cost-effective. Biopharma companies globally have turned to licensing agreements as a strategy to access innovative drugs and strengthen pipelines as merger and acquisition investment declined in 2024.
However, the proposed US BIOSECURE Act (potentially to be enacted in 2025) would prohibit federal funding for US biotech using Chinese biotech services. Additionally, the America First Investment Policy (announced on 21 February 2025) aims to restrict Chinese investments in the US biotech sector and proposes tariffs on China that could further strain supply chains and increase costs. These measures could increase geopolitical tensions, limiting Chinese biopharma’s access to US funding, partnerships and market opportunities.
In December 2024, Merck expanded its oncology pipeline, licensing LM-299, a Phase II PD-1/VEGF bispecific antibody, from LaNova Medicines in a deal worth up to $3.28 billion. Biopharmaceutical companies increasingly focus on licensing monoclonal antibodies and antibody-drug conjugates (ADCs), expanding their portfolios with advanced targeted therapies. Monoclonal antibody licensing from China rose 43% to $11.3 billion, while ADC licensing grew 10% to $10 billion in 2024. In January 2024, Novartis signed a $4.35 billion deal with Shanghai Argo Biopharmaceutical, securing an exclusive licence outside Greater China for a Phase I/IIa cardiovascular asset and a global licence for another Phase I asset, with options for two more.
这个药能不能被FDA 批是风险很大的事，就是看Pfizer的眼光。
所以网传covid 是中美合作搞出来的，真不一定是空穴来风